21262-52-2

Basic information

• Product Name: 2'-CHLOROPROPIONANILIDE
• Synonyms: 2'-CHLOROPROPIONANILIDE;N-Phenyl-2-chloro-2-methylacetamide;N-Phenyl-2-chloropropionamide;2-chloro-N-phenylpropanamide(SALTDATA: FREE);NSC99819;T0517-5848
• CAS NO: 21262-52-2
• Molecular Formula: C₉H₁₀ClNO
• Molecular Weight: 183.6348
• Mol File: 21262-52-2.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 340.232 °C at 760 mmHg
• Flash Point: 159.567 °C
• Appearance: /
• Density: 1.218 g/cm³
• Vapor Pressure: 8.72E-05mmHg at 25°C
• Refractive Index: 1.576
• CAS DataBase Reference: 2'-CHLOROPROPIONANILIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2'-CHLOROPROPIONANILIDE(21262-52-2)
• EPA Substance Registry System: 2'-CHLOROPROPIONANILIDE(21262-52-2)

Safety Data

• Hazardous Substances Data: 21262-52-2(Hazardous Substances Data)

Usage

General Description

2'-Chloropropionanilide is a chemical compound with the molecular formula C9H10ClNO. It is a pale yellow solid with a slightly sweet odor, and it is commonly used as a chemical intermediate in the synthesis of pharmaceuticals and agrochemicals. 2'-Chloropropionanilide is also known for its insecticidal and acaricidal properties, making it useful in the production of insecticides and miticides. Additionally, it has been used as a precursor for the synthesis of various fine chemicals and dyes. It is important to handle 2'-Chloropropionanilide with care, as it is considered harmful if swallowed, inhaled, or if it comes into contact with skin.

InChI:InChI=1/C9H10ClNO/c1-7(10)9(12)11-8-5-3-2-4-6-8/h2-7H,1H3,(H,11,12)

Upstream product

• 106942-22-7 lactanilide 
• 19103-79-8 2-chloro-propionyl isothiocyanate 
• 62-53-3 aniline 
• 7623-09-8 2-chloropropionyl chloride 
• 103-84-4 Acetanilid 
• 10026-13-8 phosphorus pentachloride 
• 71-43-2 benzene 
• 67097-66-9 N-chloro-propionanilide 
• 598-78-7 (R,S)-2-chloropropionic acid 
• 42308-20-3 2-bromopropionanilide 

Downstream Products

• 21262-08-8 N-(4-bromophenyl)-2-chloropropanamide 
• 21486-50-0 2-imino-5-methyl-3-phenyl-thiazolidin-4-one 
• 60093-25-6 (5-methyl-4-oxo-3-phenyl-thiazolidin-2-ylidene)-cyanamide 
• 457-46-5 2-fluoro-N-phenylpropanamide 
• 81931-33-1 N-phenyl-2-pyrrolidinyl-propionamide 
• 131859-61-5 2-(6-Methoxy-2,2-dimethyl-4-oxo-chroman-7-yloxy)-N-phenyl-propionamide 
• 131859-59-1 2-(2,2-Dimethyl-4-oxo-chroman-7-yloxy)-N-phenyl-propionamide 
• 768-52-5 N-Isopropylaniline 
• 125506-46-9 diethyl (1-oxo-1-(phenyl-amino)propan-2-yl)phosphonate 
• 596808-18-3 2-(2-chloropyridin-3-yloxy)-N-phenylpropionamide 
• 620-71-3 N-(phenyl)-2-methylacetamide 
• 150-60-7 dibenzyl disulphide 
• 333453-59-1 N-phenyl-2-(benzylthio)propanamide 
• 936908-72-4 N-phenyl-Z-3-chloro-2-(benzylthio)propenamide 

Relevant articles and documents

Optimization of bifunctional piperidinamide derivatives as σ1R Antagonists/MOR agonists for treating neuropathic pain

Here, we describe the optimization, synthesis, and associated pharmacological analgesic activities of a new series of bifunctional piperidinamide derivatives as sigma-1 receptor (σ1R) antagonists and mu opioid receptor (MOR) agonists. The new compounds were evaluated in vitro in σ1R and MOR binding assays. The most promising compound 114 (also called HKC-126), showed superior affinities for σ1R and MOR and good selectivity to additional receptors related to pain. Compound 114 showed powerful dose-dependent analgesic effects in the acetic acid writhing test, formalin test, hot plate test, and chronic constriction injury (CCI) neuropathic pain model. In contrast to an equianalgesic dose of fentanyl, compound 114 produced fewer opioid-like side effects, such as reward liability, respiratory depression, physical dependence, and sedation. Lastly, the pharmacokinetic properties of this drug were also acceptable, and these results suggest that compound 114, as a mixed σ1R/MOR ligand, has potential for treating neuropathic pain.

Inhibitory Effects of New Mercapto Xanthine Derivatives in Human mcf7 and k562 Cancer Cell Lines

A series of new 2-methyl-2-[(1,3-Diethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)thio]-N- substituted arylacetamides were synthesized. The antitumor activity of these purine based compounds were evaluated on breast cancer (MCF7) and leukemic cancer (K562) cell lines via cell viability assay utilizing the tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). These results were substantiated using computer docking experiments (LigandFit docking engine and PMF scoring function) which predict that the antitumor activity of these new compounds may be attributable to their abilities to effectively bind and block oncogenic tyrosine kinases, particularly bcr/abl.

Acetobenzylamide piperazine derivative and application thereof as cranial nerve protective agent

The invention discloses an acetobenzylamide piperazine derivative and an application thereof as a cranial nerve protective agent. Pharmacological experiments verify that the compound disclosed by the invention shows an obvious effect against glutamic acid-induced neuron exitotoxicity in vitro and obvious anti-anoxia activity in a mouse, and a herg test further shows that the compound disclosed by the invention does not have the risk of cardiotoxicity. Therefore, the compound disclosed by the invention has the advantages of being high in activity, less in side effect and good in druggability. The compound and a medicinal preparation thereof have a good curative effect for treating cranial nerve injury diseases, for example, stroke and related diseases and do not have the risk of cardiotoxicity. The acetobenzylamide piperazine derivative is a free alkali or salt of a compound with a chemical structural formula shown in the description.